ImmunoPrecise Names Dr. Dion Neame to Strategic Advisory Board

Products You May Like

VICTORIA, British Columbia — IMMUNOPRECISE ANTIBODIES LTD. (the “Firm” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a pacesetter in full-service, therapeutic antibody discovery and growth, at the moment introduced that Dr. Dion Neame has joined the corporate’s Strategic Advisory Board (SAB). Dr. Neame joins at a big time, as the corporate continues to focus its vitality on constructing important partnerships and increasing its quickly rising share of the market. He’ll play a key function in supporting the strategic and scientific prioritization of partnerships and stakeholder communications.

Dr. Neame is a medical drugs and vaccine knowledgeable, centered on medical methods for varied indications and early pipeline merchandise, in addition to exterior medical and scientific stakeholder engagements.

With over 15 years’ expertise in giant pharma, Dr. Neame has held many spectacular management roles, together with North American Senior Medical Knowledgeable and Nation Medical Lead, Canada. He additionally has intensive expertise as a medical skilled, together with pediatric drugs at notable hospitals resembling McMaster Youngsters’s Hospital and as Chief of Pediatrics Joseph Brant Hospital in Ontario, Canada.

“The addition of Dr. Neame to our SAB is instrumental in serving to to deliver IPA to the subsequent degree of development and strategic execution,” famous Dr. Jennifer Bathtub, ImmunoPrecise’s CEO. “His scientific experience in translational analysis, medical governance and compliance requirements, mixed together with his experience in stakeholder engagement, will play an vital function as we execute on our strategic plans. It’s fantastic to have somebody with Dr. Neame’s breadth and depth of expertise – from each a enterprise and scientific perspective – to hitch us at this thrilling second for IPA.”

Dr. Neame, the 2020 recipient of the Modern Medicines Revered Accomplice Award, who additionally serves as a consulting pediatrician, has concurrently held the place of Assistant Scientific Professor at McMaster College (Hamilton, Ontario) within the Division of Pediatrics for over 20 years. All through his profession, Dr. Neame has contributed to quite a few vaccine analysis packages and has been instrumental in establishing the medical, scientific and well being financial rationale for 16 new vaccination packages in provinces and territories throughout Canada.

“I stay up for becoming a member of ImmunoPrecise’s Strategic Advisory Board,” said Dr. Neame. “We live in turbulent instances and the necessity for novel therapeutic antibodies with broad epitope protection has by no means been extra vital, to go with COVID-19 vaccines to regulate SARS-CoV-2 variants of concern. IPA is a world-class Contract Analysis Group (CRO), wealthy in science and housing cutting-edge antibody platform applied sciences. The Firm’s customized approaches allow a number of antibody pathways, offering agile and adaptable discoveries to match agile and adaptable infectious microorganisms, as showcased of their work focusing on SARS-CoV-2.”

ImmunoPrecise Antibodies Ltd.

IPA is an innovation-driven, expertise platform firm that helps its pharmaceutical and biotechnology firm companions of their quest to find and develop novel, therapeutic antibodies in opposition to all courses of illness targets. The Firm goals to remodel the traditional, multi-vendor, product growth mannequin by bringing progressive and high-throughput, data-driven applied sciences to its companions, incorporating some great benefits of numerous antibody repertoires with the Firm’s therapeutic antibody discovery suite of applied sciences, to take advantage of antibodies of broad epitope protection, a number of antibody codecs, valency and dimension, and to find antibodies in opposition to a number of/uncommon epitopes. For additional data, go to www.immunoprecise.com or contact solutions@immunoprecise.com.